Alnylam Pharmaceuticals, Inc. NMS · ALNY
Price alert —
Sign in to get a one-time email the moment ALNY crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · ALNY
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1.2B | $0.2B | $0.3B | $0.0B | 17.6% | 23.0% |
| 2025-12-31 | $1.1B | $0.2B | $0.1B | $0.1B | 17.0% | 12.0% |
| 2025-09-30 | $1.2B | $0.3B | $0.4B | $0.3B | 20.1% | 29.5% |
| 2025-06-30 | $0.8B | $-0.1B | $-0.0B | $0.1B | -8.6% | -2.1% |
| 2025-03-31 | $0.6B | $-0.0B | $0.0B | $-0.1B | -3.1% | 3.0% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare ALNY vs peers
Line ALNY up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with ALNY
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-04-30 | 1.99 | 1.47 | +35.3% | -4.3% |
| 2026-02-12 | 1.25 | 1.50 | -16.5% | +1.9% |
| 2025-10-30 | 2.90 | 1.75 | +66.1% | +1.4% |
| 2025-07-31 | 0.32 | 0.15 | +119.6% | +2.4% |
| 2025-05-01 | -0.01 | -0.37 | +97.3% | +1.7% |
| 2025-02-13 | 0.06 | -0.14 | +142.5% | -3.2% |
| 2024-10-31 | -0.50 | -0.39 | -26.7% | +2.8% |
| 2024-08-01 | 0.56 | -0.69 | +181.1% | +1.3% |
| 2024-05-02 | -0.16 | -0.63 | +74.5% | +1.3% |
| 2024-02-15 | -0.77 | -0.77 | -0.2% | -0.3% |
| 2023-11-02 | 1.74 | -0.96 | +281.9% | +3.6% |
| 2023-08-03 | -1.62 | -1.34 | -21.2% | -2.4% |
| 2023-05-04 | -1.06 | -1.43 | +25.7% | +3.2% |
| 2023-02-23 | -1.39 | -1.48 | +6.3% | -3.3% |
| 2022-10-27 | -1.58 | -1.38 | -14.6% | +5.4% |
| 2022-07-28 | -2.03 | -1.36 | -49.4% | -1.0% |
| 2022-04-28 | -1.49 | -1.46 | -2.1% | -6.8% |
| 2022-02-10 | -1.69 | -1.26 | -34.4% | -0.1% |
| 2021-10-28 | -1.51 | -1.24 | -21.4% | -1.6% |
| 2021-08-03 | -1.30 | -1.28 | -1.2% | +2.6% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| ALNY ★ | $36B | 66.9 | 19.9 | 8.3 | 44.2 | 33.1 | 80.8% | 96.4% | — | 0.57% |
| LLY | $1,047B | 41.7 | 26.2 | — | 30.1 | 33.6 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $386B | 32.0 | 19.2 | 0.9 | 17.7 | 3.9 | 19.5% | 0.4% | 61.5% | 5.89% |
| JNJ | $608B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $314B | 36.0 | 13.2 | — | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.47% |
| ABBV | $451B | 125.1 | 15.7 | 7.2 | 17.2 | -67.8 | 72.0% | 12.4% | -46.2% | 4.62% |
| PFE | $143B | 19.1 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.68% |
| TMO | $196B | 29.0 | 19.4 | — | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.82% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 57.4%
| Holder | Shares | % out |
|---|---|---|
| FMR, LLC | 14,579,166 | 10.92% |
| Capital World Investors | 10,802,348 | 8.09% |
| Blackrock Inc. | 10,444,908 | 7.82% |
| Capital Research Global Investors | 9,471,181 | 7.09% |
| Vanguard Portfolio Management LLC | 6,491,280 | 4.86% |
| JPMORGAN CHASE & CO | 6,323,752 | 4.74% |
| Vanguard Capital Management LLC | 5,946,706 | 4.45% |
| T. Rowe Price Investment Management, | 5,193,324 | 3.89% |
| Invesco Ltd. | 4,075,120 | 3.05% |
| State Street Corporation | 3,322,698 | 2.49% |
Insider activity · 90d
8 buys / 5 sells · ratio 1.6 · Finnhub
- Cravatt Benjamin BUY 4,393
- PYOTT DAVID E I M 0
- PYOTT DAVID E I SELL 1,582 @ $302.65
- PYOTT DAVID E I SELL 1,599 @ $300.72
- PYOTT DAVID E I SELL 2,094 @ $299.87
- PYOTT DAVID E I SELL 3,316 @ $298.91
- PYOTT DAVID E I SELL 4,491 @ $297.71
- PYOTT DAVID E I M 5,412
- Sigal Charles Elliott BUY 1,441
- Sigal Charles Elliott BUY 1,446
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-06-03 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-03 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-05-27 | 8-K | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-22 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-14 | PRIMARY DOCUMENT | view · |
| 10-Q | 2026-04-30 | 10-Q | view · |
| 8-K | 2026-04-30 | 8-K | view · |
| 4 | 2026-04-07 | PRIMARY DOCUMENT | view · |
| DEF 14A | 2026-04-06 | DEF 14A | view · |
| 4 | 2026-03-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-04 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-04 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-04 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-04 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-04 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-04 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-03-04 | 8-K | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-25 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 10-K | 2026-02-12 | 10-K | view · |
| 8-K | 2026-02-12 | 8-K | view · |
| 4 | 2026-01-14 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-14 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-14 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-14 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-14 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2026-01-07 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-12-11 | 8-K | view · |
| 8-K | 2025-12-03 | 8-K | view · |
| 4 | 2025-12-01 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-19 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-14 | PRIMARY DOCUMENT | view · |
| 10-Q | 2025-10-30 | 10-Q | view · |
| 8-K | 2025-10-30 | 8-K | view · |
| 4 | 2025-10-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-10-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-10-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-10-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-10-03 | PRIMARY DOCUMENT | view · |
About ALNY
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight managemen…
Options picks · ALNY
ITM + OTM ideas from the latest scanLoading…
Congress trades · ALNY
STOCK Act disclosuresLoading…
SEC filings & insiders · ALNY
EDGAR · liveLoading…
Holders · ALNY
Institutions & insider activityLoading…